


1/13



2/13




FIG. 2A

3/13




FIG.2B

4/13




FIG. 3A




FIG. 3B

BEST AVAILABLE COPY

5/13




FIG. 4A



FIG. 4B

Non-treated




FIG. 5A

Doxorubicin-treated tumors




FIG. 5C




FIG. 5B

7/13




FIG. 6

8/13

	Control	Doxo (2x20 mg/ kg)
Tumor/ Kidney	0.86	0.59
Tumor/ Heart	1.07	5.69
Tumor/ Liver	0.88	4.68
Tumor/ Muscle	1.61	8.66
Tumor/ Fat tissue	6.60	5.20
Tumor/ Spleen	2.42	3.86
Tumor/ Lung	1.07	2.52
Tumor/ Blood	1.43	3.50
Tumor/Small intestine	1.18	2.26
Tumor	0.07	1.28

FIG. 7

9/13




FIG. 8B




FIG. 8A

BEST AVAILABLE COPY

10/13




FIG. 9B





FIG. 9A


BEST AVAILABLE COPY

11/13



Ischemic kidney

FIG. 10A



Contralateral side kidney

FIG. 10B

BEST AVAILABLE COPY

12/13




FIG. 11

BEST AVAILABLE COPY

13/13




FIG. 12